Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

For Consumers

Hepsera (adefovir dipivoxil) package insert updated

On November 29, 2012, FDA approved a labeling change for Hepsera (adefovir dipivoxil) package insert to include the following information under Section 5.5, Coadministration with Other Products, and to Section 17.1, Patient Counseling Information/Instructions for Safe Use.

  • Hepsera should not be used concurrently with Stribild (elvitegravir/cobicistat/emtricitabine/tenofovir disporoxil fumarate combination tablet).

Hepsera is nucleotide analogue for the treatment of chronic hepatitis B infection, manufactured by Gilead Sciences.
 
The complete, up-to-date Hepsera label may be viewed at Drugs@FDA.
 
Richard Klein
Office of Special Health Issues
Food and Drug Administration
 
Kimberly Struble
Division of Antiviral Products
Food and Drug Administration

 

Page Last Updated: 08/22/2014
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.